FindTrial
Sign In

A study for early warning predictors of mitral valve disease complicated with atrial fibrillation

A study for early warning predictors of mitral valve disease complicated with atrial fibrillation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019870
Enrollment
Unknown
Registered
2018-12-02
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

mitral valve disease complicated with atrial fibrillation:radiofrequency ablation

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients undergoing mitral valve replacement and radiofrequency ablation of atrial fibrillation and left atrial appendectomy

Exclusion criteria

Exclusion criteria: Left atrial thrombus, severe tricuspid regurgitation, severe ablation or stenosis in the aortic valve, and removal of patients with severe hypertension, severe coronary heart disease, hyperthyroidism, cardiomyopathy, and chronic pulmonary heart disease. Patients who recently took an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker (within five drug half-lives) were not included in the study.

Design outcomes

Primary

MeasureTime frame
Collagen;Matrix metalloproteinase;tissue inhibitor of metalloproteinase;—

Countries

China

Contacts

Public ContactYongjun Qian

Department of cardiovascular surgery, West China Hospital, Sichuan University

qianyongjun@scu.edu.cn+86 18980606851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026